[go: up one dir, main page]

SG10201702292YA - Novel attenuated dengue virus strains for vaccine application - Google Patents

Novel attenuated dengue virus strains for vaccine application

Info

Publication number
SG10201702292YA
SG10201702292YA SG10201702292YA SG10201702292YA SG10201702292YA SG 10201702292Y A SG10201702292Y A SG 10201702292YA SG 10201702292Y A SG10201702292Y A SG 10201702292YA SG 10201702292Y A SG10201702292Y A SG 10201702292YA SG 10201702292Y A SG10201702292Y A SG 10201702292YA
Authority
SG
Singapore
Prior art keywords
dengue virus
virus strains
attenuated dengue
vaccine application
novel attenuated
Prior art date
Application number
SG10201702292YA
Inventor
Katja Fink
Pei-Yong Shi
cheng feng Qin
Original Assignee
Agency Science Tech & Res
Novartis Ag
Beijing Inst Of Microbiology And Epidemiology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Novartis Ag, Beijing Inst Of Microbiology And Epidemiology filed Critical Agency Science Tech & Res
Publication of SG10201702292YA publication Critical patent/SG10201702292YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24162Methods of inactivation or attenuation by genetic engineering
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201702292YA 2012-09-21 2013-09-23 Novel attenuated dengue virus strains for vaccine application SG10201702292YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG2012070421 2012-09-21

Publications (1)

Publication Number Publication Date
SG10201702292YA true SG10201702292YA (en) 2017-05-30

Family

ID=50341781

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502221WA SG11201502221WA (en) 2012-09-21 2013-09-23 Novel attenuated dengue virus strains for vaccine application
SG10201702292YA SG10201702292YA (en) 2012-09-21 2013-09-23 Novel attenuated dengue virus strains for vaccine application

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201502221WA SG11201502221WA (en) 2012-09-21 2013-09-23 Novel attenuated dengue virus strains for vaccine application

Country Status (4)

Country Link
US (1) US20150231226A1 (en)
EP (1) EP2897628A4 (en)
SG (2) SG11201502221WA (en)
WO (1) WO2014046622A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143817A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Dengue virus vaccine
KR102297300B1 (en) * 2015-11-27 2021-09-02 케이엠 바이올로직스 가부시키가이샤 A live virus banked from an attenuated dengue virus strain, and a dengue vaccine using them as an antigen
US20190203269A1 (en) * 2016-09-07 2019-07-04 University Of Miami Tri-nucleotide rolling circle amplification
US11254712B2 (en) 2017-03-30 2022-02-22 The University Of Queensland Chimeric molecules and uses thereof
EP4400174A3 (en) 2017-09-01 2024-10-23 The Francis Crick Institute Limited Immunoregulatory molecules and uses therefor
US20220354942A1 (en) * 2021-05-09 2022-11-10 Board Of Regents, The University Of Texas System Attenuating viral mutations in protein genes
CN113604483A (en) * 2021-07-13 2021-11-05 中山大学 Dengue virus serum 3-type epidemic strain GZ14D3 replicon and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010693A1 (en) * 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system

Also Published As

Publication number Publication date
EP2897628A1 (en) 2015-07-29
SG11201502221WA (en) 2015-05-28
EP2897628A4 (en) 2016-06-22
US20150231226A1 (en) 2015-08-20
WO2014046622A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
HK1207967A1 (en) Vaccine
HK1209646A1 (en) Nasal influenza vaccine composition
IL229307A0 (en) Inactivated dengue virus vaccine
PL2647387T3 (en) Vaccine Composition
HK1212905A1 (en) Vaccine compositions for prevention against dengue virus infection
HK1212906A1 (en) Vaccine compositions
EP2806891A4 (en) Parainfluenza virus 5 based vaccines
GB201223386D0 (en) Vaccine
IL231043A (en) Vaccine
SG11201502221WA (en) Novel attenuated dengue virus strains for vaccine application
HK1212919A1 (en) Wt1 vaccine wt1
GB201119999D0 (en) Vaccine
HK1209140A1 (en) Bovine influenza c virus compositions
HK1201283A1 (en) Influenza c virus and vaccine
GB201202090D0 (en) Vaccine
GB201215184D0 (en) Therapeutic virus
HK1209647A1 (en) Dengue virus vaccine composition
GB201120000D0 (en) Vaccine
AU2013369626A1 (en) Dengue virus vaccine composition
ZA201407962B (en) Vaccine combinations
GB201210226D0 (en) Vaccine
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine
GB201211930D0 (en) Concept for all killer viruses